RevMed's pancreatic cancer pill daraxonrasib wins FDA approval at $475,000 annual cost

On August 26, 2026, Revolution Medicines Inc. secured U.S. FDA approval for daraxonrasib, branded as Rasonque, a once-daily pill that extends survival for patients with advanced pancreatic cancer. Priced at over $475,000 annually, the breakthrough treatment is one of the most expensive cancer therapies in history. Revolution Medicines Inc. made the drug commercially available immediately on the day of its approval.

Daraxonrasib FDA approval

• ▪The once-daily pill daraxonrasib, branded as Rasonque, is designed to lengthen the lives of patients with advanced pancreatic cancer, which is historically one of the hardest-to-treat tumor types.
• ▪Revolution Medicines Inc. received U.S. Food and Drug Administration approval on August 26, 2026, for its once-daily pill daraxonrasib, branded as Rasonque, to treat advanced pancreatic cancer.

$475,000 annual drug pricing

• ▪Revolution Medicines Inc. set the list price for its pancreatic cancer drug daraxonrasib (Rasonque) at more than $475,000 per year, making it one of the most expensive cancer treatments in history.
• ▪Revolution Medicines Inc. made its newly approved pancreatic cancer drug daraxonrasib (Rasonque) commercially available starting on Wednesday, August 26, 2026.

2 sources